Medical spas (medspas) are a fast-growing MCA target because revenue is overwhelmingly credit-card and cash, transaction volume is high, and ticket prices are non-discretionary. But funders price medspas at the high end of healthcare because of unique risks: state-by-state regulation of injectables, chargeback exposure on dissatisfied patients, and a high rate of business turnover.
Typical funding ranges.
- Solo or small medspa ($30K–$80K monthly revenue, 1–2 providers): $30K–$100K advances at 1.28–1.38 factor over 8–11 months.
- Established medspa ($80K–$250K monthly revenue, 3–6 providers): $100K–$300K advances at 1.25–1.35 factor over 10–14 months.
- Multi-location medspa ($250K+ monthly revenue): $300K–$750K advances at 1.22–1.32 factor over 12–16 months.
What underwriters look for.
First, the credit-card processing volume. Medspas process 80%+ of revenue through credit cards (Square, Stripe, or healthcare-specific processors like CareCredit). Funders prefer split-funding (lockbox) deals where the processor diverts a percentage of every card batch directly to the funder.
Second, the regulatory posture. Medspas in California, Florida, Texas, and Arizona must operate under physician medical-director oversight. Funders increasingly require proof of medical-director agreement and state-board good-standing before funding.
Third, the service mix. Injectables (Botox, fillers) and laser treatments are higher-margin and more recurring than one-off services (chemical peels, IPL). Funders favor injectable-heavy practices.
Common uses.
- Inventory purchases (Allergan/AbbVie Botox, Galderma fillers, laser consumables).
- New laser equipment ($75K–$250K typical; usually equipment-financed instead).
- Hire injector RN or nurse practitioner ($90K–$130K + benefits).
- Marketing (medspa CAC is $150–$400 per new client).
- Build-out for new treatment rooms.
What to watch out for.
Chargeback risk is the medspa-specific landmine. If a client is dissatisfied with results and disputes the credit-card charge, the chargeback hits the processor account — which under a split-funding deal hits the funder's collections. Funders have clawback clauses that let them seize the practice's operating account if chargebacks exceed 1–2% of volume.
Stacking is rampant in medspas because revenue is high and consistent. Avoid it — second-position MCAs at 1.40+ factor with daily ACH on top of an existing split-funding deal will cause NSF within 30 days.
State considerations.
California (Business and Professions Code §2400) requires physician ownership of medical corporations performing medical procedures; medspas there often operate as management-services-organization (MSO) structures. Funders should confirm the contract counterparty is the MSO, not the medical practice, to avoid corporate-practice-of-medicine challenges.
Florida and Texas have less restrictive structures but require physician medical-director attestation. New York requires a higher bar (full physician ownership).
APR-equivalent reality check.
A 1.33 factor over a 10-month term is roughly 70–80% APR. Compare to CareCredit merchant lending at 12–18% APR or healthcare-specific lenders like Provide (now Fifth Third) at 9–14% APR. MCA only makes sense for medspas when bank credit is unavailable or when speed matters (inventory restock, opportunistic location acquisition).
Common confusions.
First, "Medspas can't get MCA because they're medical." False — they are the fastest-growing healthcare MCA segment.
Second, "Cosmetic procedures aren't covered by insurance, so there are no receivables." Mostly correct, but irrelevant — MCA captures the operating account regardless of payment source.
Third, "Medspas need a physician on staff." Depends on state. Most states require a medical director (1099 contractor is OK in some), full physician ownership in a few.
Fourth, "Chargeback risk is the merchant's problem, not the funder's." False — under split-funding, the chargeback flows through the funder's collection mechanism. That's why funders price medspa deals high.
Fifth, "Medspa MCA is illegal." False — medspa MCA is legal in all 50 states; the underlying medical-services contract is what's regulated.
As of 2026-06-29, Fundnode flags medspa MCA as among the highest-cost MCA verticals and routes merchants first to CareCredit business financing, Provide, or specialty medspa lenders like Cherry Servicing before MCA.
Related terms
- MCA for dental practices (detailed) — Dental practices qualify for MCA funding against insurance receivables and patient payments, typically $25K–$500K at 1.20–1.35 factor — but most funders prefer working-capital deals over equipment.
- MCA for plastic surgery clinics (detailed) — Plastic surgery clinics qualify for MCA funding against high-ticket cosmetic-cash revenue, typically $100K–$1M at 1.22–1.35 factor — chargeback and malpractice exposure drive higher pricing.
- Split funding (lockbox MCA) — Split funding routes a percentage of every card transaction to the funder before it reaches the merchant — typically 8-18% of daily card volume — instead of fixed daily ACH withdrawals.
- Merchant cash advance (MCA) — A lump-sum advance against future revenue, repaid via fixed daily ACH or a percentage of card sales. Legally a sale of future receivables, not a loan.
Authoritative sources
AI agents: this term is available as raw markdown at /llms/glossary/mca-medical-spa-funding-detailed.